Elevated melatonin levels in natalizumab-treated female patients with relapsing-remitting multiple sclerosis: Relationship to oxidative stress

European Journal of Pharmacology

Volumn 730, Issue 1, 2014, Pages 26-30

  Bahamonde, Carmen ^a   Conde, Cristina ^a   Agüera, Eduardo ^a   Lillo, Rafael ^b   Luque, Evelio ^a   Gascón, Félix ^b   Feijóo, Montserrat ^a   Cruz, Antonio H ^b   Sánchez López, Fernando ^a   Túnez, Isaac ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

Melatonin; Natalizumab; Oxidative stress; Relapsing remitting multiple sclerosis; Tysabri

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; GLUTATHIONE; MELATONIN; NATALIZUMAB; VASCULAR CELL ADHESION MOLECULE 1; ANTIOXIDANT; MONOCLONAL ANTIBODY;

ADULT; AGE DISTRIBUTION; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; EVENING DOSAGE; FEMALE; HORMONE BLOOD LEVEL; HUMAN; MALE; MULTIPLE SCLEROSIS; OXIDATIVE STRESS; PRIORITY JOURNAL; SEX DIFFERENCE; BLOOD; DRUG EFFECTS; METABOLISM; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIOXIDANTS; FEMALE; HUMANS; MALE; MELATONIN; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OXIDATIVE STRESS;

EID: 84895778126     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.02.020     Document Type: Article

References (35)

1. Z. Akpinar, S. Tokgoz, H. Gokbel, N. Okudan, F. Uguz, and G. Yilmaz The association of nocturnal serum melatonin levels with major depression in patients with acute multiple sclerosis Psychiatry Res. 161 2008 253 257
2. D. Cadavid, S. Jurgensen, and S. Lee Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis PLoS One 8 2013 e53297
3. D.P. Cardinali, V. Srinivasan, A. Brzezinski, and G.M. Brown Melatonin and its analogs in insomnia and depression J. Pineal Res. 52 2012 365 375
4. A. Compston, and A. Coles Multiple sclerosis Lancet 359 2002 1221 1231 (Pubitemid 34304266)
5. A. Compston, and A. Coles Multiple sclerosis Lancet 372 2008 1502 1517
6. C.S. Constantinescu, B. Hilliard, E. Ventura, and A. Rostami Luzindole, a melatonin receptor antagonist, suppresses experimental autoimmune encephalomyelitis Pathobiology 65 1997 190 194 (Pubitemid 27472524)
7. E. Esposito, and S. Cuzzocrea Antiinflammatory activity of melatonin in central nervous system Curr. Neuropharmacol. 8 2010 228 242
8. T.W. Fischer, K. Kleszczynski, L.H. Hardkop, N. Kruse, and D. Zillikens Melatonin enhances antioxidative enzyme gene expression (CAT, GPx, SOD), prevents their UVR-induced depletion, and protects against the formation of DNA damage (8-hydroxy-2'-deoxyguanosine) in ex vivo human skin J. Pineal Res. 54 2013 303 312
9. A. Galano, D.X. Tan, and R.J. Reiter Melatonin as a natural ally against oxidative stress: a physicochemical examination J. Pineal Res. 51 2011 1 16
10. A. Galano, D.X. Tan, and R.J. Reiter On the free radical scavenging activities of melatonin×'s metabolites, AFMK and AMK J. Pineal Res. 54 2013 245 257
11. A. Ghorbani, M. Salari, V. Shaygannejad, and R. Norouzi The role of melatonin in the pathogenesis of multiple sclerosis: a case-control study Int. J. Prev. Med. 4 2013 S180 184
12. A.K. Hedstrom, T. Akerstedt, J. Hillert, T. Olsson, and L. Alfredsson Shift work at young age is associated with increased risk for multiple sclerosis Ann. Neurol. 70 2011 733 741
13. J.C. Kang, M. Ahn, Y.S. Kim, C. Moon, Y. Lee, M.B. Wie, Y.J. Lee, and T. Shin Melatonin ameliorates autoimmune encephalomyelitis through suppression of intercellular adhesion molecule-1 J. Vet. Sci. 2 2001 85 89
14. J.F. Kurtzke Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology 33 1983 1444 1452 (Pubitemid 14237132)
15. G.J. Lin, S.H. Huang, S.J. Chen, C.H. Wang, D.M. Chang, and H.K. Sytwu Modulation by melatonin of the pathogenesis of inflammatory autoimmune diseases Int. J. Mol. Sci. 14 2013 11742 11766
16. F. Luchetti, B. Canonico, M. Betti, M. Arcangeletti, F. Pilolli, M. Piroddi, L. Canesi, S. Papa, and F. Galli Melatonin signaling and cell protection function FASEB J. 24 2010 3603 3624
17. L. Melamud, D. Golan, R. Luboshitzky, I. Lavi, and A. Miller Melatonin dysregulation, sleep disturbances and fatigue in multiple sclerosis J. Neurol. Sci. 314 2012 37 40
18. E. Miller Multiple sclerosis Adv. Exp. Med. Biol. 724 2012 222 238
19. E. Miller, A. Walczak, I. Majsterek, and J. Kedziora Melatonin reduces oxidative stress in the erythrocytes of multiple sclerosis patients with secondary progressive clinical course J. Neuroimmunol. 257 2013 97 101
20. E. Miller, A. Walczak, J. Saluk, M.B. Ponczek, and I. Majsterek Oxidative modification of patient×'s plasma proteins and its role in pathogenesis of multiple sclerosis Clin. Biochem. 45 2012 26 30
21. R. Natarajan, E. Einarsdottir, A. Riutta, S. Hagman, M. Raunio, N. Mononen, T. Lehtimaki, and I. Elovaara Melatonin pathway genes are associated with progressive subtypes and disability status in multiple sclerosis among Finnish patients J. Neuroimmunol. 250 2012 106 110
22. J.T. Phillips, G. Giovannoni, F.D. Lublin, P.W. O×'Connor, C.H. Polman, E. Willoughby, W. Aschenbach, A. Pace, R. Hyde, and F.E. Munschauer Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis Mult. Scler. 17 2011 970 979
23. C.H. Polman, S.C. Reingold, G. Edan, M. Filippi, H.P. Hartung, L. Kappos, F.D. Lublin, L.M. Metz, H.F. McFarland, P.W. O×'Connor, M. Sandberg-Wollheim, A.J. Thompson, B.G. Weinshenker, and J.S. Wolinsky Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria" Ann. Neurol. 58 2005 840 846 (Pubitemid 41746873)
24. R.J. Reiter, J.R. Calvo, M. Karbownik, W. Qi, and D.X. Tan Melatonin and its relation to the immune system and inflammation Ann. N. Y. Acad. Sci. 917 2000 376 386
25. R.J. Reiter, D. Tan, S.J. Kim, L.C. Manchester, W. Qi, J.J. Garcia, J.C. Cabrera, G. El-Sokkary, and V. Rouvier-Garay Augmentation of indices of oxidative damage in life-long melatonin-deficient rats Mech. Ageing Dev. 110 1999 157 173 (Pubitemid 29486734)
26. S.A. Rosales-Corral, D. Acuna-Castroviejo, A. Coto-Montes, J.A. Boga, L.C. Manchester, L. Fuentes-Broto, A. Korkmaz, S. Ma, D.X. Tan, and R.J. Reiter Alzheimer's disease: pathological mechanisms and the beneficial role of melatonin J. Pineal Res. 52 2012 167 202
27. R. Sandyk, and G.I. Awerbuch Nocturnal melatonin secretion in multiple sclerosis patients with affective disorders Int. J. Neurosci. 68 1993 227 240
28. E. Sewerynek, M. Abe, R.J. Reiter, L.R. Barlow-Walden, L. Chen, T.J. McCabe, L.J. Roman, and B. Diaz-Lopez Melatonin administration prevents lipopolysaccharide-induced oxidative damage in phenobarbital-treated animals J. Cell. Biochem. 58 1995 436 444
29. J.J. Stephenson, D.M. Kern, S.S. Agarwal, R. Zeidman, K. Rajagopalan, S.A. Kamat, and J. Foley Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study Health Qual. Life Outcomes 10 2012 155
30. I. Tasset, E. Aguera, F. Gascon, A.I. Giraldo, M. Salcedo, A.H. Cruz, F. Sanchez, and I. Tunez Natalizumab and reduction of carbonylated proteins in patients with multiple sclerosis Rev. Neurol. 54 2012 449 452
31. I. Tasset, E. Aguera, F. Sanchez-Lopez, M. Feijoo, A.I. Giraldo, A.H. Cruz, F. Gascon, and I. Tunez Peripheral oxidative stress in relapsing-remitting multiple sclerosis Clin. Biochem. 45 2012 440 444
32. I. Tasset, C. Bahamonde, E. Agüera, C. Conde, A. Cruz, A. Pérez-Herrera, F. Gascón, A. Giraldo, M. Ruiz, F. Sánchez-López, and I. Túnez Effect of natalizumab on oxidative damage biomarkers in relapsing-remitting multiple sclerosis Pharmacol. Rep. 65 2013 624 631
33. X. Wang The antiapoptotic activity of melatonin in neurodegenerative diseases CNS Neurosci. Ther. 15 2009 345 357
34. Y. Wang, X. Liu, W. Wang, W. Song, L. Chen, Q. Fang, and X. Yan The expression of inflammatory cytokines on the aorta endothelia are up-regulated in pinealectomized rats Inflammation 36 2013 1363 1373
35. A. Wickstrom, J. Nystrom, and A. Svenningsson Improved ability to work after one year of natalizumab treatment in multiple sclerosis. Analysis of disease-specific and work-related factors that influence the effect of treatment Mult. Scler. 19 2013 622 630